Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,234 matching trials from the live ClinicalTrials.gov search.
Conditions
Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic, Small Cell Lung Cancer
Interventions
BBI-355, Erlotinib, Futibatinib, BBI-825
Drug
Lead sponsor
Boundless Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
Los Angeles, California • Santa Monica, California • Denver, Colorado + 12 more
Conditions
Rheumatoid Arthritis
Interventions
AC430
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Respiratory Tract Infections
Interventions
RD19
Device
Lead sponsor
EmitBio Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Raleigh, North Carolina
Conditions
Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Solid Tumor
Interventions
IPN01194
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Los Angeles, California • San Diego, California • New Haven, Connecticut + 2 more
Conditions
Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Non-squamous, Non-Small Cell Lung Cancer, Endometrial Adenocarcinoma, Ovarian Adenocarcinoma, Primary Peritoneal Carcinoma
Interventions
ETX-929 dose escalation, ETX-929 dose escalation in combination with cetuximab
Drug
Lead sponsor
Ensem Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Fairfax, Virginia
Conditions
Solid Malignant Tumor
Interventions
TVB-2640
Drug
Lead sponsor
Sagimet Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
7
States / cities
Scottsdale, Arizona • Denver, Colorado • Sarasota, Florida + 4 more
Conditions
Hematological Malignancies
Interventions
Teclistamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 6 more
Conditions
Advanced Solid Cancer, Metastatic Solid Cancer
Interventions
BI 3819026, Ezabenlimab (BI 754091)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
New Haven, Connecticut • Hackensack, New Jersey • New York, New York + 1 more
Conditions
Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers, Epithelial Tumor, Biliary Tract Cancer (BTC), Urothelial Cancer, Nasopharyngeal Cancers
Interventions
AVZO-1418, Combination Agent 1, Combination Agent 2
Drug
Lead sponsor
Avenzo Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
19
States / cities
Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 15 more
Terminated Phase 1 Interventional Accepts healthy volunteers

GSK706769 A First Time in Human Study For Males and Females

NCT00539201
Conditions
Healthy Subjects
Interventions
GSK706769
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Advanced Solid Tumor, BRAF V600 Mutation
Interventions
ABM-1310, Cobimetinib
Drug
Lead sponsor
ABM Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
San Francisco, California • Stanford, California • Miami, Florida + 4 more
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, First-in-human Study of VX-668

NCT05727800
Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
VX-668, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
5
States / cities
Tempe, Arizona • Gainesville, Florida • Orlando, Florida + 2 more
Conditions
Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent, Non-squamous EGFR Wt NSCLC, Platinum Resistant Ovarian Cancer, PROC
Interventions
HWK-007
Drug
Lead sponsor
Whitehawk Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
12
States / cities
Little Rock, Arkansas • Los Angeles, California • Peoria, Illinois + 9 more
Conditions
Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC), Renal Cell Carcinoma(RCC), Urothelial Carcinoma, Malignant Melanoma
Interventions
Phase 1a: LB-LR1109, Phase 1b: LB-LR1109 and Atezolizumab
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Fairfax, Virginia
Conditions
Atopic Dermatitis
Interventions
RPT193, Placebo
Drug
Lead sponsor
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
13
States / cities
Anniston, Alabama • Scottsdale, Arizona • San Diego, California + 10 more
Conditions
Advanced Solid Tumors
Interventions
BAY3375968, Pembrolizumab
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Chapel Hill, North Carolina • San Antonio, Texas + 1 more
Conditions
Neurogenic Detrusor Overactivity, Spinal Cord Injuries
Interventions
EG110A
Drug
Lead sponsor
Cyllene Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Downey, California • Ann Arbor, Michigan • Columbus, Ohio + 2 more
Conditions
Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma
Interventions
ELI-002 2P
Drug
Lead sponsor
Elicio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more
Conditions
Community-acquired Pneumonia, Bacterial Pneumonia
Interventions
CMTX-101, Placebo
Drug
Lead sponsor
Clarametyx Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
8
States / cities
Augusta, Georgia • Idaho Falls, Idaho • Louisville, Kentucky + 5 more
Conditions
Locally Advanced or Metastatic HER2-Expressing Cancers
Interventions
VIR-5818, pembrolizumab
Drug
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
Duarte, California • Palo Alto, California
Completed Phase 1 Interventional Accepts healthy volunteers

First Time in Human Study of Protexia

NCT00744146
Conditions
Intervention for Nerve Agent Exposure
Interventions
Protexia
Biological
Lead sponsor
PharmAthene, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Metastatic Castration-resistant Prostate Cancer (CRPC), Metastatic Castration-resistant Prostate Carcinoma
Interventions
(R)-9bMS
Drug
Lead sponsor
TechnoGenesys, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia
Interventions
SAR443579
Drug
Lead sponsor
Sanofi
Industry
Eligibility
1 Year and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
10
States / cities
Duarte, California • Atlanta, Georgia • Boston, Massachusetts + 7 more
Conditions
Neuropathic Pain From Lumbosacral Radiculopathy
Interventions
KLS-2031, Placebo
Drug · Other
Lead sponsor
Kolon Life Science
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah